Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6977371 | 0.77 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL7134856 | 0.76 | ALDH1A1 (0.55) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL6984832 | 0.74 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL6984835 | 0.74 | ALDH1A1 (0.52) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL5091684 | 0.73 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1HPGDLMNA | |
| SCHEMBL24711757 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL6987305 | 0.72 | ALDH1A1 (0.46) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL8626579 | 0.72 | ALDH1A1 (0.53) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL6984502 | 0.72 | ALDH1A1 (0.57) | ALDH1A1KMT2AMEN1HPGDMAPT | |
| SCHEMBL31480810 | 0.72 | ALDH1A1 (0.49) | ALDH1A1KMT2AMEN1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1292585-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | disclosed |
| WO-2001098282-A1 | BENZOXAZEPINONES AND THEIR USE AS SQUALENE SYNTHASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078251-A1 | Benzoxazepinones and their use as squalene synthase inhibitors | SQLE, CYP17A1, ACOX1 | ALDH1A1 1026/4885KMT2A 2350/4885MEN1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.